| # | Title | Journal | Year | Citations |
|---|
| 1 | Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen | Drug Development Research | 1995 | 1,425 |
| 2 | Magnetic nanoparticles for drug delivery | Drug Development Research | 2006 | 723 |
| 3 | Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics | Drug Development Research | 2020 | 636 |
| 4 | Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor-targeted drug delivery vectors | Drug Development Research | 2006 | 409 |
| 5 | Comparison of the proteolytic susceptibilities of homologous L-amino acid, D-amino acid, and N-substituted glycine peptide and peptoid oligomers | Drug Development Research | 1995 | 383 |
| 6 | Ectonucleotidases: Some recent developments and a note on nomenclature | Drug Development Research | 2001 | 367 |
| 7 | Anticonvulsant activity of (+)-5-methyl-10, 11-dihydro-5H-dibenzo[a, d]cyclohepten-5, 10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties | Drug Development Research | 1982 | 351 |
| 8 | Mitogen-inducible prostaglandin G/H synthase: A new target for nonsteroidal antiinflammatory drugs | Drug Development Research | 1992 | 289 |
| 9 | The Role of miR‐21 in Cancer | Drug Development Research | 2015 | 283 |
| 10 | Integrin αvβ3‐targeted cancer therapy | Drug Development Research | 2008 | 267 |
| 11 | Next‐generation antimalarial drugs: hybrid molecules as a new strategy in drug design | Drug Development Research | 2010 | 254 |
| 12 | Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo [a, d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties | Drug Development Research | 1982 | 238 |
| 13 | Network Pharmacology: A Rosetta Stone for Traditional Chinese Medicine | Drug Development Research | 2014 | 224 |
| 14 | Dose translation between laboratory animals and human in preclinical and clinical phases of drug development | Drug Development Research | 2018 | 214 |
| 15 | Targeted nanoparticles for detecting and treating cancer | Drug Development Research | 2006 | 202 |
| 16 | 1,4-Dihydropyridine Ca2+ channel antagonists and activators: A comparison of binding characteristics with pharmacology | Drug Development Research | 1984 | 194 |
| 17 | Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine | Drug Development Research | 1991 | 192 |
| 18 | Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker | Drug Development Research | 1986 | 191 |
| 19 | Mechanisms of cholinesterase inhibition in senile dementia of the alzheimer type: Clinical, pharmacological, and therapeutic aspects | Drug Development Research | 1988 | 189 |
| 20 | Current drug targets for Alzheimer's disease treatment | Drug Development Research | 2002 | 181 |
| 21 | Molecular architecture of G protein-coupled receptors | Drug Development Research | 1996 | 180 |
| 22 | Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies | Drug Development Research | 2004 | 177 |
| 23 | Time-dependent sensitization as the cornerstone for a new approach to pharmacotherapy: Drugs as foreign/stressful stimuli | Drug Development Research | 1988 | 171 |
| 24 | Gangliosides in treatment of neural injury and disease | Drug Development Research | 1988 | 161 |
| 25 | Viruses and their uses in nanotechnology | Drug Development Research | 2006 | 161 |
| 26 | Carbonic anhydrase: General perspective and advances in glaucoma research | Drug Development Research | 1987 | 157 |
| 27 | Extracellular purine metabolism | Drug Development Research | 1996 | 154 |
| 28 | Enhanced delivery of drugs into and across the skin by ethosomal carriers | Drug Development Research | 2000 | 150 |
| 29 | Natural products and colon cancer: current status and future prospects | Drug Development Research | 2008 | 149 |
| 30 | Numbering of cloned P2 purinoceptors | Drug Development Research | 1996 | 146 |
| 31 | Biopolymer albumin for diagnosis and in drug delivery | Drug Development Research | 2003 | 145 |
| 32 | Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip | Drug Development Research | 2000 | 144 |
| 33 | Neurochemical mechanisms mediating the behavioral and cognitive effects of nicotine | Drug Development Research | 1994 | 143 |
| 34 | Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type | Drug Development Research | 1988 | 140 |
| 35 | Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1 | Drug Development Research | 2001 | 140 |
| 36 | Novel therapeutics with enhanced biological activity generated by the strategic introduction of silicon isosteres into known drug scaffolds | Drug Development Research | 2007 | 140 |
| 37 | Cyclodextrin complexes: Perspective from drug delivery and formulation | Drug Development Research | 2018 | 140 |
| 38 | Pharmacological profile of ritanserin: A very specific central serotonin S2-antagonist | Drug Development Research | 1988 | 138 |
| 39 | Restoration of shock-suppressed behavior by treatment with (+)-5-methyl-10,11-dihydro-5H-dibenzo[a, d]cyclohepten-5, 10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties | Drug Development Research | 1982 | 137 |
| 40 | Amphiphilic block copolymer micelles for nanoscale drug delivery | Drug Development Research | 2006 | 137 |
| 41 | Physiological and pathological roles of purines: An update | Drug Development Research | 1993 | 134 |
| 42 | Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems | Drug Development Research | 2019 | 131 |
| 43 | Alfentanil (R 39 209) ? a particularly short-acting intravenous narcotic analgesic in rats | Drug Development Research | 1981 | 126 |
| 44 | Androgen sensitivity gateway to COVID‐19 disease severity | Drug Development Research | 2020 | 126 |
| 45 | Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin | Drug Development Research | 1996 | 123 |
| 46 | Preparation and characterization of drug-loaded chitosan-tripolyphosphate microspheres by spray drying | Drug Development Research | 2005 | 122 |
| 47 | Nootropic drugs: Animal models for studying effects on cognition | Drug Development Research | 1984 | 121 |
| 48 | Potential antipsychotic BMY 14802 selectively binds to sigma sites | Drug Development Research | 1987 | 121 |
| 49 | Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders and stress | Drug Development Research | 1984 | 120 |
| 50 | Calcium channels: Structure, function, and classification | Drug Development Research | 1994 | 119 |
